TITLE

New generic drugs could lead to health-care savings

AUTHOR(S)
Tampone, Kevin
PUB. DATE
December 2005
SOURCE
Business Journal (Central New York);12/23/2005, Vol. 19 Issue 51, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article presents information about the pharmaceutical market in New York. According to Joel Owerbach, vice president and chief pharmacy officer for Excellus BlueCross BlueShield, a rush of new generic drugs will be storming the pharmaceutical market starting in 2006. It will allow people to save money on prescription drugs. Experts believe that during the next three years, brand-name drugs, whose sales total $10 billion to $12 billion, will become available as generics. The new generic drugs will be chemically identical to their brand-name counterparts.
ACCESSION #
19363434

 

Related Articles

  • CHAGING LANDSCAPES. Gray, Nicole // Pharmaceutical Executive;May2006, Vol. 26 Issue 5, p77 

    The article provides insights on the world's top 50 pharmaceutical companies. According to the IMS data, the global market registered a 7 percent growth in 2005, led by the biologics sector. It adds that the generic market registered a 13 percent growth. It notes that generic prescription volume...

  • Generic Rx Has Majority of Market, IMS Study Shows. Toth, Wendy // SN: Supermarket News;3/17/2008, Vol. 56 Issue 11, p25 

    The article focuses on a study which found that generic prescriptions account for a large part of the pharmaceutical market in the U.S. According to the study, 65 percent of all U.S. prescriptions dispensed are filled with generics. It also noted that as a number of big-name drugs are set to...

  • The International Pharmaceutical Market as a Source of Low-Cost Prescription Drugs for U.S. Patients. Kesselheim, Aaron S.; Choudhry, Niteesh K. // Annals of Internal Medicine;4/15/2008, Vol. 148 Issue 8, p614 

    In response to increasing prescription drug costs, more U.S. patients and policymakers are importing less-expensive pharmaceutical products from other countries. Large-scale prescription drug importation is currently illegal, but the U.S. Food and Drug Administration permits individuals to bring...

  • Best may be yet to come for generic drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p28 

    Reports on the research-and-development pipeline of drug makers in the U.S. Sales of generic companies; Factors contributing to the performance of drug makers; Development of generic pipeline.

  • GPhA bullish on generic industry's future. Cohen, Harold E. // Drug Topics;5/7/2001, Vol. 145 Issue 9, p64 

    Provides information on the Generic Pharmaceutical Association (GPhA), a unification of the generic industry in the United States. Significance of the formation of a united front for the generic industry; Goals of the association; Strategy of pharmacy benefit managers.

  • Is the Generics Industry Ready for Multi-Source Biologics? Challener, Cynthia // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p14 

    Deals with the generic biologic industry. Estimated growth of the biopharmaceutical generics market; Details on the acquisition of Indiana Protein Technologies by Ivax Corp.; European firms preparing to participate in the marketing and sales of generic biopharmaceuticals; Risks faced by a...

  • Pharmaceutical policy regarding generic drugs in Belgium. Simoens, Steven; De Bruyn, Kristien; Bogaert, Marc; Laekeman, Gert // PharmacoEconomics;2005, Vol. 23 Issue 8, p755 

    Pressure to control pharmaceutical expenditure and price competition among pharmaceutical companies are fuelling the development of generic drug markets in EU countries. However, in Belgium, the market for generic drugs is underdeveloped compared with other countries. To promote the use of...

  • GENERIC DISPENSING: The potential pitfalls of generic substitution. Tennant, Allan // GP: General Practitioner;6/5/2009, p60 

    The article focuses on implementation of generic substitution of drugs in Great Britain. It states that generic substitution was negotiated as part of the Pharmaceutical Price Regulation Scheme agreement in which manufacturers receive the support from the government to encourage the uptake of...

  • Generic prices hold steady, widening distance from branded Rx. Frederick, James // Drug Store News;9/26/2005, Vol. 27 Issue 12, p56 

    Reports that generic drug prices in the U.S. held steady in the first quarter of 2005. Widening of the price gap between branded and generic pharmaceuticals; Impact of generic drugs on the Medicare Part D drug benefit program; Observation that price increases in branded drugs continued to exceed...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics